AIM ImmunoTech's Ampligen Shows 50% ORR in Ovarian Cancer Trial, Hinting at Immunotherapy Breakthrough

Event summary

  • AIM ImmunoTech's Ampligen achieved a 50% objective response rate (ORR) in a Phase 2 trial for recurrent ovarian cancer, including 21% complete responses.
  • The trial, conducted with UPMC and Merck, showed a 79% clinical benefit rate and median overall survival of 32.5 months with no Grade 4 or 5 toxicities.
  • Secondary endpoint data, including progression-free survival, is expected to be completed in January 2027.
  • Ampligen's intellectual property protection extends into 2039, with potential applications in multiple cancer types.

The big picture

This trial result positions Ampligen as a potential key to overcoming immunotherapy resistance in ovarian cancer, a significant challenge in oncology. The data suggests Ampligen could expand the reach of checkpoint inhibitors, a multi-billion-dollar market, into more refractory cancer types. AIM ImmunoTech's ability to leverage this breakthrough will depend on securing partnerships and navigating regulatory hurdles efficiently.

What we're watching

Clinical Validation
Whether Ampligen can sustain these results in larger, later-stage trials across multiple cancer types.
Strategic Partnerships
The pace at which AIM ImmunoTech secures additional collaborations to advance Ampligen's development.
Regulatory Pathway
How quickly Ampligen can navigate regulatory approvals for expanded indications in oncology.